logo
£5,000 invested in this 9p penny stock just 1 month ago is now worth…

£5,000 invested in this 9p penny stock just 1 month ago is now worth…

Yahoo7 days ago
Agronomics (LSE: ANIC) is a penny stock on the move — it's up 23.3% in just a month. This means that anyone who put five grand into Agronomics shares in mid-June would now be sitting on £6,165.
But had an investor bagged this one at just under 4p at the start of 2025, they would have done even better. Year to date, the stock has rocketed 138% to 9p!
Science fact
For those wondering, Agronomics is the backer of 20+ venture-stage companies aiming to commercialise lab-grown meat. These start-ups are harnessing innovative technologies to produce cell-cultivated meat, milk, eggs, and more.
In other words, products that remove the need to farm livestock and slaughter animals. Instead, animal cells are grown in a lab or bioreactor.
While that might sound like something out of Frankenstein, this isn't science fiction. Indeed, it's fast becoming science fact.
Take BlueNalu, for example, which is one of Agronomics' portfolio bets. This is a US-based firm pioneering cell-cultivated seafood. Its first product is bluefin tuna, which is one of the world's most overfished species.
The company grows the seafood in bioreactors, cell by cell. That means no heads, tails, bones, or microplastics — just pure fillets.
Again, this isn't just pie-in-the-sky stuff. BlueNalu has expanded a deal with Nomad Foods, the frozen food firm behind Birds Eye and Findus, to support the future commercialisation of its seafood products in the UK and Europe.
According to a survey sponsored by BlueNalu, 92% of 2,000 frequent sushi eaters in the UK expressed interest in trying the product. If BlueNalu achieves regulatory approval and commercial rollout, the value of Agronomics' investment could soar.
Another firm backed by Agronomics — called Meatly — has cut bioreactor costs by 95%. This moves its cultivated pet food, which was launched in Pets at Home in February, closer to price parity with conventional chicken.
Frankenfood fears
It's tricky to put a valuation on Agronomics. Most of the companies it holds are still making their way towards commercialisation.
But in March, Agronomics' net asset value (NAV) was calculated at 14.93p. With the shares now at 9p, this suggests a NAV discount of about 40%. On this basis, the shares are still undervalued, despite doubling this year.
However, it's important to understand that this is a high-risk stock. Some of these firms could go bust due to a lack of funding or a failure to successfully launch products.
Also, there may well be a backlash against lab-grown meat. The Trump administration could make US regulatory approvals and funding more difficult.
Moreover, the US meat industry and agribusiness groups are obviously going to put up a fight. I expect to see plenty many 'Frankenfood' posts and headlines over the next few years.
Adventurous
Still, this technology is potentially revolutionary. As Agronomics argues, 'We are on the cusp of the deepest, fastest, most consequential disruption in food and agricultural production since the first domestication of plants and animals 10,000 years ago.'
Given the fact that Agronomics invested in these start-ups at the ground floor level, the returns could be enormous if a couple of them succeed in future. But that's not guaranteed.
Therefore, this is the very definition of a high-risk, high-reward penny stock. Only the most adventurous investors should consider it.
The post £5,000 invested in this 9p penny stock just 1 month ago is now worth… appeared first on The Motley Fool UK.
More reading
5 Stocks For Trying To Build Wealth After 50
One Top Growth Stock from the Motley Fool
Ben McPoland has no position in any of the shares mentioned. The Motley Fool UK has recommended Pets At Home Group Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.
Motley Fool UK 2025
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Why Google should 'walk away' from Waymo
Why Google should 'walk away' from Waymo

Yahoo

time21 minutes ago

  • Yahoo

Why Google should 'walk away' from Waymo

Needham & Company senior media and internet analyst Laura Martin joins Market Domination with Josh Lipton to explain why Alphabet (GOOG, GOOGL) should ditch Waymo and focus on generative artificial intelligence (AI) instead. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. Related videos The £70bn pension tax raid Reeves may not be able to resist 10 shares I wouldn't want to hold in a stock market crash After falling 16% in a day, this stock's on my list of shares to buy in August This FTSE 250 trust is easily beating the global index in 2025. Time to buy? Sign in to access your portfolio

Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY
Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY

Yahoo

time21 minutes ago

  • Yahoo

Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY

BioNTech SE and Pfizer recently received a positive recommendation from the European Medicines Agency for marketing authorization of their COVID-19 vaccine, which likely contributed to Pfizer's share price increase of 8% in the last quarter. The company's advancements in COVID-19 vaccine development, alongside other product-related announcements like the XTANDI and BRAFTOVI trial results, added weight to this upward movement. Despite legal challenges and declining earnings, Pfizer's focus on innovation and strategic partnerships like the one with XtalPi possibly countered broader market moves, which saw a smaller 1% increase in the same period. We've identified 3 warning signs for Pfizer that you should be aware of. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. The recent positive recommendation from the European Medicines Agency for the COVID-19 vaccine developed by BioNTech SE and Pfizer has contributed to an 8% increase in Pfizer's share price over the last quarter. This news may provide a temporary boost to Pfizer's revenue and earnings forecasts, especially as the company continues to innovate amidst legal challenges and declining earnings. The authorization could enhance immediate market confidence in Pfizer's product pipeline, impacting future revenue projections positively. Over the past year, Pfizer experienced a total return of 13.78% including dividends, reflecting a challenging period for shareholders. When compared to the broader US market's return of 17.2% over the same period, Pfizer has underperformed, highlighting investor concerns over competitive pressures and revenue growth prospects. The current share price movement toward the analyst consensus price target of $29.23 suggests a cautiously optimistic outlook among some market participants. Analysts' revenue forecasts reflect potential declines due to increased competition for existing products, yet others anticipate that strategic shifts in research focus, especially in oncology, might mitigate future earnings risks. With a modest increase of 8% in shares largely tied to vaccine authorization, it underscores the uncertainty surrounding longer-term performance relative to bearish analyst expectations. Understand Pfizer's track record by examining our performance history report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include PFE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@

Pixel 10 Pro Price Leak Confirms Google's Bold Decisions
Pixel 10 Pro Price Leak Confirms Google's Bold Decisions

Forbes

time23 minutes ago

  • Forbes

Pixel 10 Pro Price Leak Confirms Google's Bold Decisions

Pixel 9 Pro XL As Google prepares to announce the Pixel 10 and Pixel 10 Pro in late August, some of the biggest questions have been about the price of the new handsets. With flagship phones from the likes of Apple and Samsung regularly pushing base models into four-figure prices, how competitive will Google's pricing decisions be and what do they say about its strategy? Pixel 10 And Pixel 10 Pro Pricing We have European pricing across the four main models, which are broadly similar to the pricing of the Pixel 9 family. The Pixel 10 starts at €899 for 128 GB, the Pixel 10 Pro at €1,099 also for 128 GB, and the Pixel 10 Pro XL listings drop the 128 GB option to start at €1,299 for 256 GB. Finally, the Pixel 10 Pro Fold starts at € 1,899 for 256 GB. Both the Pro XL and the Pro Fold, sitting at the top of the portfolio, do not have 128 GB versions listed. That's not to say the 128 GB option is definitely gone—perhaps these will be available only through the Google Store, region-locked, or as network exclusives. We shall see during the Made By Google launch event scheduled for Aug. 20. By echoing 2024's pricing across the range, Google offers us a glimpse into the wider strategy it is using to address both the consumer market and its Android Partners. Pixel 10 And Pixel 10 Pro Strategy The steady approach to pricing—which is arguably mirrored by the incremental updates to the physical design of the Pixel 10 family over the Pixel 9—shows Google's confidence in the market. There may be new features added to the hardware and software of the Pixel package, but the value proposition has not changed; so neither has the price. That could be a quiet victory on retail shelves. There's an expectation that the price of the new model will rise compared to the existing model. Because the counterpoint to this is that if Google did lift the prices on the Pixel models, then the difference between its smartphones and the likes of the iPhone Pro or Galaxy S Ultra models would be more apparent; the increased performance of the latter would be noticeable, and the value conscious consumer would look at the closer pricing and decide that the jump to a more recognisable phone brand would be easier to make. Yet there is something more for the price-conscious buyer. Because of the lower starting price for each model, moving up to a model with increased storage feels like good value, in part due to keeping the Pixels lower than the entry-level pricing of the aforementioned Apple and Samsung devices. Finding Value In The Pixel 10 And Pixel 10 Pro Pricing for the Pixel 10 Pro and the rest of the Pixel 10 lineup is familiar. Google continues to offer a flagship experience at a price that will be perceived as lower than that of its competitors' flagships. Part of me wonders if this is because the real value in the Pixel family for Google is in the software and subscription services such as Google One and Google Gemini. Now read the latest Pixel 10 Pro, Samsung Galaxy, and smartphone news in Forbes' weekly Android news digest...

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store